Ginkgo Bioworks DNA Private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4
Private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4 at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Ginkgo Bioworks in its filing.
Tagged under the XBRL concept us-gaap:FinancingReceivableExcludingAccruedInterestAfterAllowanceForCreditLoss.
The official record: Ginkgo Bioworks’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4?
- Ginkgo Bioworks (DNA) reported private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4 of $7.5M in Q1 2026.
- How has Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4 changed year-over-year?
- Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4 decreased by 69.9% year-over-year, from $24.9M to $7.5M.
- What is the long-term trend for Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4?
- Over 3 years (2022 to 2025), Ginkgo Bioworks's private debt held-for-investment, at amortized cost, net of valuation allowance – $3 and $4 has grown at a 9.0% compound annual growth rate (CAGR), from $7.5M to $9.7M.